Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.

Antimicrobial agents and chemotherapy - 20 Sept 2022

Poulton Nicholas C, Azadian Zachary A, DeJesus Michael A, Rock Jeremy M

Abstract excerpt

Tuberculosis (TB) is the leading cause of death from any bacterial infection, causing 1.5 million deaths worldwide each year. Due to the emergence of drug-resistant strains of Mycobacterium tuberculosis (Mtb) there have been significant efforts aimed at developing novel drugs to treat TB. One promising drug target in Mtb is the arabinogalactan biosynthetic enzyme DprE1, and there have been over a dozen unique...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Diarylquinolines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microbial Sensitivity Tests

Share to Mycobacterium tuberculosis

Share to Piperazines

Share to Spiro Compounds

Share to Tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 35920665
DOI: 10.1128/aac.00904-22
PMCID: PMC9487612

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.PMID 35920665Read ↗

Mutations in <i>rv0678</i> confer low-level resistance to benzothiazinone DprE1 inhibitors in <i>M. tuberculosis</i>Semantic proximity Read ↗

Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.Semantic proximity Read ↗

Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678Semantic proximity Read ↗

Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Whole Genome Sequencing Identifies Novel Mutations Associated With Bedaquiline Resistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosisSemantic proximity Read ↗

N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.Semantic proximity Read ↗

Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis.Semantic proximity Read ↗

A chemical-genetic map of the pathways controlling drug potency in <i>Mycobacterium tuberculosis</i>Semantic proximity Read ↗

MarR-Dependent Transcriptional Regulation of <i>mmpSL5</i> induces Ethionamide Resistance in <i>Mycobacterium abscessus</i>Semantic proximity Read ↗

Side Chain-modified Benzothiazinone Derivatives with Anti-Mycobacterial ActivitySemantic proximity Read ↗

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.